Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (FDY.F)
Frankfurt · EUR · Healthcare · Drug Manufacturers - Specialty & Generic
€0.27 (-0.74%) as of
Key statistics
- Market cap
- 281.61M
- EPS (TTM)
- -0.0100
- Dividend yield
- 0.00%
- 52-week range
- 0.2340 – 0.3660
- Beta
- 0.06
- Revenue (TTM)
- 667.94M
- Profit margin
- -18.90%
- Volume
- 2.76k
About Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China. It offers photodynamic technology drugs, such as aminolevulinic acid hydrochloride and hemoporfin for Injection; doxorubicin liposome under the Libord brand; genetic engineering drugs; and oral solid preparation technology drugs. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Shanghai, China
- Employees
- 833
fd-zj.com/DesktopModules/HT/chinese/home/Index.aspx
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.